Literature DB >> 31186860

Nonalcoholic fatty liver disease: Definitions, risk factors, and workup.

Puneet Puri1, Arun J Sanyal1.   

Abstract

Entities:  

Year:  2012        PMID： 31186860      PMCID： PMC6499283          DOI： 10.1002/cld.81

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  7 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Gastroenterology       Date:  2012-05-15       Impact factor: 22.682

3.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Patricia Belt; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

4.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

Review 5.  Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research.

Authors:  David E Kleiner; Elizabeth M Brunt
Journal:  Semin Liver Dis       Date:  2012-03-13       Impact factor: 6.115

6.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

7.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425
  7 in total
  27 in total

Review 1.  Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.

Authors:  Sandra Torres; Paula Segalés; Carmen García-Ruiz; José C Fernández-Checa
Journal:  Cells       Date:  2022-04-27       Impact factor: 7.666

2.  Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids.

Authors:  Jie Jian; Mei-Tong Nie; Baoyu Xiang; Hui Qian; Chuan Yin; Xin Zhang; Menghui Zhang; Xuan Zhu; Wei-Fen Xie
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

3.  Integrated quantitative susceptibility and R2 * mapping for evaluation of liver fibrosis: An ex vivo feasibility study.

Authors:  Ramin Jafari; Stefanie J Hectors; Anne K Koehne de González; Pascal Spincemaille; Martin R Prince; Gary M Brittenham; Yi Wang
Journal:  NMR Biomed       Date:  2020-09-22       Impact factor: 4.044

Review 4.  Targeting the eicosanoid pathway in hepatocellular carcinoma.

Authors:  Anshuli Razdan; Nathan M Main; Vincent Chiu; Nicholas A Shackel; Paul de Souza; Katherine Bryant; Kieran F Scott
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 5.  Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand.

Authors:  Rajvi Gor; Nabeel A Siddiqui; Ransirini Wijeratne Fernando; Archana Sreekantan Nair; Janan Illango; Mushrin Malik; Pousette Hamid
Journal:  Cureus       Date:  2021-05-05

6.  Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational Studies.

Authors:  Vladimir T Ivashkin; Marina V Maevskaya; Elena N Shirokova; Igor V Maev; Alexey A Samsonov; Evgeniy I Sas; Liudmila K Palgova; Kirill Starostin
Journal:  Drugs Real World Outcomes       Date:  2021-05-15

7.  Association of [1H]-MRS quantified liver fat content with glucose metabolism status.

Authors:  Yun-Sheng Wang; Jun Ye; Yong-Hong Cao; Rong Zhang; Xiao-Fang Han; Ling-Ling Zou; Lei Kuang; Ji Zhang; Hu Lian; Jin-Xiang Xia; Qiu Zhang; Wu Dai
Journal:  Diabetol Metab Syndr       Date:  2020-06-08       Impact factor: 3.320

Review 8.  Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.

Authors:  Saumya Jayakumar; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2019-05-31       Impact factor: 8.171

9.  An albino mouse model of nonalcoholic fatty liver disease induced using high-fat liquid "Lieber-DeCarli" diet: a preliminary investigation.

Authors:  Ayokanmi Ore; Regina Ngozi Ugbaja; Abideen Idowu Adeogun; Oluseyi Adeboye Akinloye
Journal:  Porto Biomed J       Date:  2020-07-17

10.  Reference range of liver corrected T1 values in a population at low risk for fatty liver disease-a UK Biobank sub-study, with an appendix of interesting cases.

Authors:  A Mojtahed; C J Kelly; A H Herlihy; S Kin; H R Wilman; A McKay; M Kelly; M Milanesi; S Neubauer; E L Thomas; J D Bell; R Banerjee; M Harisinghani
Journal:  Abdom Radiol (NY)       Date:  2019-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.